Why Adaptimmune (ADAP) Stock Is Plunging Today - TCR2 Therapeutics (NASDAQ:TCRR), Adaptimmune Therapeutics (NASDAQ:ADAP)

Adaptimmune to acquire Boston-area cell therapy company TCR² Therapeutics

Adaptimmune Therapeutics, a cell therapy developer with offices in Philadelphia and the United Kingdom, is acquiring TCR² Therapeutics of Cambridge, Massachusetts, in an all-stock transaction. Under the terms of the deal, AdaptImmune (NASDAQ: ADAP) shareholders will own 75% of the combined company. TCR² (NASDAQ: TCRR) stockholders will receive 1.51 Adaptimmune American depository shares for each TCR² share they own, giving them the remaining 25%…

Why Adaptimmune (ADAP) Stock Is Plunging Today - TCR2 Therapeutics (NASDAQ:TCRR), Adaptimmune Therapeutics (NASDAQ:ADAP)

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat...

TCRR - Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms.

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms